Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies
نویسندگان
چکیده
منابع مشابه
Novel CD20 monoclonal antibodies for lymphoma therapy
Rituximab (RTX), a monoclonal antibody (mAb) against CD20, has been widely used for lymphoma therapy. RTX in combination with cyclophosphamide /doxorubicin /vincristine /prednisone (R-CHOP) remains the standard frontline regimen for diffuse large B-cell lymphoma. However, suboptimal response and /or resistance to rituximab have remained a challenge in the therapy of B-cell non-Hodgkin's lymphom...
متن کاملMonoclonal antibodies targeting CD20
We are commenting on the article by Klein et al. on the functional properties of several anti-CD20 monoclonal antibodies (mAbs) in the January/February 2013 issue of mAbs. 1 Rituximab, the first monoclonal antibody approved for cancer therapy, has truly revolutionized the treatment of a variety of CD20 + hema-tological malignancies, 2,3 and also has been studied in a large number of autoimmune ...
متن کاملGeneration of CD20-specific TCRs for TCR gene therapy of CD20low B-cell malignancies insusceptible to CD20-targeting antibodies
Immunotherapy of B-cell leukemia and lymphoma with CD20-targeting monoclonal antibodies (mAbs) has demonstrated clinical efficacy. However, the emergence of unresponsive disease due to low or absent cell surface CD20 urges the need to develop additional strategies. In contrast to mAbs, T-cells via their T-cell receptor (TCR) can recognize not only extracellular but also intracellular antigens i...
متن کاملAnti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
BACKGROUND While most antibody-based therapies use IgG because of their well-known biological properties, some functional limitations of these antibodies call for the development of derivatives with other therapeutic functions. Although less abundant than IgG in serum, IgA is the most abundantly produced Ig class in humans. Besides the specific targeting of its dimeric form to mucosal areas, Ig...
متن کاملDevelopment of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
Rituximab has been revolutionized and validated CD20 targeting monoclonal antibody. Although, it is widely used for lymphoma therapy and many patients have been benefited. However significant numbers of patients are refractory or developed resistance to current therapies due to low level of CD20 expression and/or availability on cells surface. Thus development of novel anti-CD20 mAbs with great...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: mAbs
سال: 2020
ISSN: 1942-0862,1942-0870
DOI: 10.1080/19420862.2020.1795505